{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T21:47:18Z","timestamp":1770328038890,"version":"3.49.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T00:00:00Z","timestamp":1593129600000},"content-version":"am","delay-in-days":269,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.bone.2019.06.018","type":"journal-article","created":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T08:27:16Z","timestamp":1561105636000},"page":"199-206","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Zoledronate and Raloxifene combination therapy enhances material and mechanical properties of diseased mouse bone"],"prefix":"10.1016","volume":"127","author":[{"given":"Katherine M.","family":"Powell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cayla","family":"Skaggs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis","family":"Pulliam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alycia","family":"Berman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew R.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6077-8058","authenticated-orcid":false,"given":"Joseph M.","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2019.06.018_bb0005","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bone.2011.04.022","article-title":"Bisphosphonates: the first 40 years","volume":"49","author":"Russell","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.bone.2019.06.018_bb0010","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"Osteoporosis prevention, diagnosis, and therapy","volume":"285","author":"NIH","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.bone.2019.06.018_bb0015","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclic administration of pamidronate in children with severe osteogenesis imperfecta","volume":"339","author":"Glorieux","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2019.06.018_bb0020","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy","volume":"19","author":"Russell","year":"2008","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2019.06.018_bb0025","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.bone.2010.10.159","article-title":"Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: what we think we know and what we know that we don't know","volume":"49","author":"Allen","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.bone.2019.06.018_bb0030","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00198-008-0754-4","article-title":"Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate","volume":"20","author":"Tang","year":"2009","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2019.06.018_bb0035","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00198-007-0533-7","article-title":"Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra","volume":"19","author":"Allen","year":"2008","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2019.06.018_bb0040","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.bone.2015.08.002","article-title":"Alendronate treatment alters bone tissues at multiple structural levels in healthy canine cortical bone","volume":"81","author":"Acevedo","year":"2015","journal-title":"Bone"},{"key":"10.1016\/j.bone.2019.06.018_bb0045","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1023\/A:1010019410881","article-title":"Mechanism of action and preclinical profile of raloxifene, a selective estrogen receptor modulation","volume":"2","author":"Bryant","year":"2001","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"10.1016\/j.bone.2019.06.018_bb0050","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00198-005-2030-1","article-title":"Anti-vertebral fracture efficacy of raloxifene: a meta-analysis","volume":"17","author":"Seeman","year":"2006","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2019.06.018_bb0055","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1185\/03007995.2011.606312","article-title":"Long-term raloxifene for postmenopausal osteoporosis","volume":"27","author":"Recker","year":"2011","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.bone.2019.06.018_bb0060","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) investigators","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.bone.2019.06.018_bb0065","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.bone.2014.01.009","article-title":"Bone cell-independent benefits of raloxifene on the skeleton: a novel mechanism for improving bone material properties","volume":"61","author":"Gallant","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.bone.2019.06.018_bb0070","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.bmc.2015.12.045","article-title":"Structural features underlying raloxifene's biophysical interaction with bone matrix","volume":"24","author":"Bivi","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bone.2019.06.018_bb0075","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/(SICI)1098-1004(1997)9:4<300::AID-HUMU2>3.0.CO;2-9","article-title":"Mutations in fibrillar collagens (types I, II, III, and XI), fibril-associated collagen (type IX), and network-forming collagen (type X) cause a spectrum of diseases of bone, cartilage, and blood vessels","volume":"9","author":"Kuivaniemi","year":"1997","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.bone.2019.06.018_bb0080","doi-asserted-by":"crossref","first-page":"12941","DOI":"10.1016\/S0021-9258(18)90635-6","article-title":"Osteogenesis imperfecta: cloning of a pro-alpha 2(I) collagen gene with a frameshift mutation","volume":"259","author":"Pihlajaniemi","year":"1984","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bone.2019.06.018_bb0085","doi-asserted-by":"crossref","unstructured":"D. W. Rowe and J. R. Shapiro, \"Osteogenesis Imperfecta,\" in Metabolic Bone Disease and Clinically Related Disorders, 3 ed: Academic Press, 1998, pp. 651\u2013683.","DOI":"10.1016\/B978-012068700-8\/50024-4"},{"key":"10.1016\/j.bone.2019.06.018_bb0090","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11832-011-0380-0","article-title":"Changing pattern of femoral fractures in osteogenesis imperfecta with prolonged use of bisphosphonates","volume":"6","author":"Nicolaou","year":"2012","journal-title":"J. Child. Orthop."},{"key":"10.1016\/j.bone.2019.06.018_bb0095","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.medengphy.2009.06.010","article-title":"A fracture risk assessment model of the femur in children with osteogenesis imperfecta (OI) during gait","volume":"31","author":"Fritz","year":"2009","journal-title":"Med. Eng. Phys."},{"key":"10.1016\/j.bone.2019.06.018_bb0100","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1210\/jcem.87.3.8325","article-title":"Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis","volume":"87","author":"Johnell","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2019.06.018_bb0105","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/jbmr.2172","article-title":"How tough is brittle bone? Investigating osteogenesis imperfecta in mouse bone","volume":"29","author":"Carriero","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.06.018_bb0110","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.bone.2007.12.215","article-title":"Role of genetic background in determining phenotypic severity throughout postnatal development and at peak bone mass in Col1a2 deficient mice (oim)","volume":"42","author":"Carleton","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.bone.2019.06.018_bb0115","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1210\/en.2007-0275","article-title":"Raloxifene enhances material-level mechanical properties of femoral cortical and trabecular bone","volume":"148","author":"Allen","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.bone.2019.06.018_bb0120","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1002\/jbmr.2470","article-title":"In vivo UTE-MRI reveals positive effects of raloxifene on skeletal-bound water in skeletally mature beagle dogs","volume":"30","author":"Allen","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.06.018_bb0125","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1007\/s00198-016-3701-9","article-title":"Zoledronate treatment has different effects in mouse strains with contrasting baseline bone mechanical phenotypes","volume":"27","author":"Aref","year":"2016","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2019.06.018_bb0130","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.matbio.2015.12.008","article-title":"Raloxifene reduces skeletal fractures in an animal model of osteogenesis imperfecta","volume":"52-54","author":"Berman","year":"2016","journal-title":"Matrix Biol."},{"key":"10.1016\/j.bone.2019.06.018_bb0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0130504","article-title":"Structural and mechanical improvements to bone are strain dependent with axial compression of the tibia in female C57BL\/6 mice","volume":"10","author":"Berman","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bone.2019.06.018_bb0140","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1359\/jbmr.081259","article-title":"Inbred strain-specific response to biglycan deficiency in the cortical bone of C57BL6\/129 and C3H\/He mice","volume":"24","author":"Wallace","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.06.018_bb0145","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.bone.2016.04.021","article-title":"Removing or truncating connexin 43 in murine osteocytes alters cortical geometry, nanoscale morphology, and tissue mechanics in the tibia","volume":"88","author":"Hammond","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.bone.2019.06.018_bb0150","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.bone.2008.04.027","article-title":"Measurement of the toughness of bone: a tutorial with special reference to small animal studies","volume":"43","author":"Ritchie","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.bone.2019.06.018_bb0155","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s00198-011-1742-7","article-title":"Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta","volume":"23","author":"Bargman","year":"2012","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2019.06.018_bb0160","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00223-017-0257-4","article-title":"Raloxifene improves bone mechanical properties in mice previously treated with zoledronate","volume":"101","author":"Meixner","year":"2017","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2019.06.018_bb0165","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.bone.2004.10.006","article-title":"Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse","volume":"36","author":"Misof","year":"2005","journal-title":"Bone"},{"key":"10.1016\/j.bone.2019.06.018_bb0170","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/jbmr.3421","article-title":"Low dose of bisphosphonate enhances sclerostin antibody-induced trabecular bone mass gains in Brtl\/+ osteogenesis imperfecta mouse model","volume":"33","author":"Olvera","year":"2018","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.06.018_bb0175","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jmbbm.2014.12.020","article-title":"Microstructure and compressive mechanical properties of cortical bone in children with osteogenesis imperfecta treated with bisphosphonates compared with healthy children","volume":"46","author":"Imbert","year":"2015","journal-title":"J. Mech. Behav. Biomed. Mater."},{"key":"10.1016\/j.bone.2019.06.018_bb0180","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.bone.2014.09.003","article-title":"Increased intra-cortical porosity reduces bone stiffness and strength in pediatric patients with osteogenesis imperfecta","volume":"69","author":"Vardakastani","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.bone.2019.06.018_bb0185","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.bone.2017.08.015","article-title":"The fracture toughness of small animal cortical bone measured using arc-shaped tension specimens: effects of bisphosphonate and deproteinization treatments","volume":"105","author":"Hunckler","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.bone.2019.06.018_bb0190","doi-asserted-by":"crossref","first-page":"8722","DOI":"10.1073\/pnas.1704460114","article-title":"Atypical fracture with long-term bisphosphonate therapy is associated with altered cortical composition and reduced fracture resistance","volume":"114","author":"Lloyd","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bone.2019.06.018_bb0195","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005088.pub3","article-title":"Bisphosphonate therapy for osteogenesis imperfecta","volume":"7","author":"Dwan","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.bone.2019.06.018_bb0200","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1002\/jbmr.2486","article-title":"Osteotomy healing in children with osteogenesis imperfecta receiving bisphosphonate treatment","volume":"30","author":"Anam","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.06.018_bb0205","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1056\/NEJMc062792","article-title":"Prolonged bisphosphonate release after treatment in children","volume":"356","author":"Papapoulos","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2019.06.018_bb0210","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/jbmr.2805","article-title":"Recurrent proximal femur fractures in a teenager with osteogenesis imperfecta on continuous bisphosphonate therapy: are we overtreating?","volume":"31","author":"Vasanwala","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.06.018_bb0215","doi-asserted-by":"crossref","first-page":"818","DOI":"10.7326\/M15-1361","article-title":"Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians","volume":"166","author":"Qaseem","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.bone.2019.06.018_bb0220","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/joim.12339","article-title":"Efficacy, effectiveness and side effects of medications used to prevent fractures","volume":"277","author":"Reid","year":"2015","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.bone.2019.06.018_bb0225","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/jbmr.3143","article-title":"BPS804 anti-sclerostin antibody in adults with moderate osteogenesis imperfecta: results of a randomized phase 2a trial","volume":"32","author":"Glorieux","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.06.018_bb0230","first-page":"24","article-title":"Safety and efficacy of denosumab in children with osteogenesis imperfect--a first prospective trial","volume":"16","author":"Hoyer-Kuhn","year":"2016","journal-title":"J. Musculoskelet. Neuronal Interact."},{"key":"10.1016\/j.bone.2019.06.018_bb0235","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.1210\/endo.138.10.5440","article-title":"Biosynthetic human parathyroid hormone (1\u201334) effects on bone quality in aged ovariectomized rats","volume":"138","author":"Sato","year":"1997","journal-title":"Endocrinology"},{"key":"10.1016\/j.bone.2019.06.018_bb0240","series-title":"The Effects of Parathyroid Hormone and Alendronate Alone or in Combination in Postmenopausal Osteoporosis","first-page":"1207","volume":"vol. 349","author":"Black","year":"2003"},{"key":"10.1016\/j.bone.2019.06.018_bb0245","series-title":"The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis","first-page":"1216","volume":"vol. 349","author":"Finkelstein","year":"2003"},{"key":"10.1016\/j.bone.2019.06.018_bb0250","series-title":"Parathyroid Hormone plus Alendronate \u2014 A Combination That Does Not Add up","first-page":"1277","volume":"vol. 349","author":"Khosla","year":"2003"},{"key":"10.1016\/j.bone.2019.06.018_bb0255","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1172\/JCI71101","article-title":"Evaluation of teriparatide treatment in adults with osteogenesis imperfecta","volume":"124","author":"Orwoll","year":"2014","journal-title":"J. Clin. Invest."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328219302509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328219302509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:46:01Z","timestamp":1757612761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328219302509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":51,"alternative-id":["S8756328219302509"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2019.06.018","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Zoledronate and Raloxifene combination therapy enhances material and mechanical properties of diseased mouse bone","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2019.06.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}